Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients

Richard Maziarz, Praseeda Sridharan, Susan Slater, Gabrielle Meyers, Mary Post, Dean D. Erdman, Teresa C T Peret, Randy A. Taplitz

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Human parainfluenza virus 3 (HPIV3) infection can cause significant morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). There are no standard guidelines for the prevention and control of HPIV3 in the outpatient setting. After 2 HSCT inpatients diagnosed with HPIV3 were noted to have had multiple recent HSCT outpatient clinic (OPC) visits, an investigation of policy and procedures in the HSCT OPC was undertaken, and active surveillance for respiratory viral illness was instituted in the at-risk HSCT population. Between July 19 and August 30, 2005, 13 patients were diagnosed with HPIV3 infection. Morbidity in affected patients was significant, and mortality was high (38.5%) and not affected by antiviral therapy. Molecular typing identified several genetically distinct groups of the hemagglutinin-neuraminidase gene of the 11 available isolates. Based on sequence relatedness among the isolates and the demographic and exposure history of the patients, in many of these cases HPIV3 infection likely was acquired in the HSCT OPC. The major infection control interventions were introduced between August 20 and August 24. An epidemic curve revealed that HPIV3 infection frequency peaked between August 17 and August 26, with no cases identified after August 30. Prompt attention and focus on infection control interventions were associated with a rapid decrease in the number of incident cases. Policies and procedures regarding patients with respiratory viral illnesses in HSCT OPC populations should be formulated and universally reinforced with HSCT clinic staff to prevent the spread of these infections.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Human parainfluenza virus 3
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Disease Outbreaks
Transplants
Paramyxoviridae Infections
Ambulatory Care Facilities
Infection Control
Morbidity
Molecular Typing
Mortality
Transplant Recipients
Hemagglutinins
Neuraminidase
Ambulatory Care
Population
Antiviral Agents
Inpatients
Outpatients
Demography

Keywords

  • Infection control
  • Parainfluenza
  • Stem cell transplant

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients. / Maziarz, Richard; Sridharan, Praseeda; Slater, Susan; Meyers, Gabrielle; Post, Mary; Erdman, Dean D.; Peret, Teresa C T; Taplitz, Randy A.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 2, 02.2010, p. 192-198.

Research output: Contribution to journalArticle

Maziarz, Richard ; Sridharan, Praseeda ; Slater, Susan ; Meyers, Gabrielle ; Post, Mary ; Erdman, Dean D. ; Peret, Teresa C T ; Taplitz, Randy A. / Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 2. pp. 192-198.
@article{c2090e35435444f495c40b23fc58de22,
title = "Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients",
abstract = "Human parainfluenza virus 3 (HPIV3) infection can cause significant morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). There are no standard guidelines for the prevention and control of HPIV3 in the outpatient setting. After 2 HSCT inpatients diagnosed with HPIV3 were noted to have had multiple recent HSCT outpatient clinic (OPC) visits, an investigation of policy and procedures in the HSCT OPC was undertaken, and active surveillance for respiratory viral illness was instituted in the at-risk HSCT population. Between July 19 and August 30, 2005, 13 patients were diagnosed with HPIV3 infection. Morbidity in affected patients was significant, and mortality was high (38.5{\%}) and not affected by antiviral therapy. Molecular typing identified several genetically distinct groups of the hemagglutinin-neuraminidase gene of the 11 available isolates. Based on sequence relatedness among the isolates and the demographic and exposure history of the patients, in many of these cases HPIV3 infection likely was acquired in the HSCT OPC. The major infection control interventions were introduced between August 20 and August 24. An epidemic curve revealed that HPIV3 infection frequency peaked between August 17 and August 26, with no cases identified after August 30. Prompt attention and focus on infection control interventions were associated with a rapid decrease in the number of incident cases. Policies and procedures regarding patients with respiratory viral illnesses in HSCT OPC populations should be formulated and universally reinforced with HSCT clinic staff to prevent the spread of these infections.",
keywords = "Infection control, Parainfluenza, Stem cell transplant",
author = "Richard Maziarz and Praseeda Sridharan and Susan Slater and Gabrielle Meyers and Mary Post and Erdman, {Dean D.} and Peret, {Teresa C T} and Taplitz, {Randy A.}",
year = "2010",
month = "2",
doi = "10.1016/j.bbmt.2009.09.014",
language = "English (US)",
volume = "16",
pages = "192--198",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients

AU - Maziarz, Richard

AU - Sridharan, Praseeda

AU - Slater, Susan

AU - Meyers, Gabrielle

AU - Post, Mary

AU - Erdman, Dean D.

AU - Peret, Teresa C T

AU - Taplitz, Randy A.

PY - 2010/2

Y1 - 2010/2

N2 - Human parainfluenza virus 3 (HPIV3) infection can cause significant morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). There are no standard guidelines for the prevention and control of HPIV3 in the outpatient setting. After 2 HSCT inpatients diagnosed with HPIV3 were noted to have had multiple recent HSCT outpatient clinic (OPC) visits, an investigation of policy and procedures in the HSCT OPC was undertaken, and active surveillance for respiratory viral illness was instituted in the at-risk HSCT population. Between July 19 and August 30, 2005, 13 patients were diagnosed with HPIV3 infection. Morbidity in affected patients was significant, and mortality was high (38.5%) and not affected by antiviral therapy. Molecular typing identified several genetically distinct groups of the hemagglutinin-neuraminidase gene of the 11 available isolates. Based on sequence relatedness among the isolates and the demographic and exposure history of the patients, in many of these cases HPIV3 infection likely was acquired in the HSCT OPC. The major infection control interventions were introduced between August 20 and August 24. An epidemic curve revealed that HPIV3 infection frequency peaked between August 17 and August 26, with no cases identified after August 30. Prompt attention and focus on infection control interventions were associated with a rapid decrease in the number of incident cases. Policies and procedures regarding patients with respiratory viral illnesses in HSCT OPC populations should be formulated and universally reinforced with HSCT clinic staff to prevent the spread of these infections.

AB - Human parainfluenza virus 3 (HPIV3) infection can cause significant morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). There are no standard guidelines for the prevention and control of HPIV3 in the outpatient setting. After 2 HSCT inpatients diagnosed with HPIV3 were noted to have had multiple recent HSCT outpatient clinic (OPC) visits, an investigation of policy and procedures in the HSCT OPC was undertaken, and active surveillance for respiratory viral illness was instituted in the at-risk HSCT population. Between July 19 and August 30, 2005, 13 patients were diagnosed with HPIV3 infection. Morbidity in affected patients was significant, and mortality was high (38.5%) and not affected by antiviral therapy. Molecular typing identified several genetically distinct groups of the hemagglutinin-neuraminidase gene of the 11 available isolates. Based on sequence relatedness among the isolates and the demographic and exposure history of the patients, in many of these cases HPIV3 infection likely was acquired in the HSCT OPC. The major infection control interventions were introduced between August 20 and August 24. An epidemic curve revealed that HPIV3 infection frequency peaked between August 17 and August 26, with no cases identified after August 30. Prompt attention and focus on infection control interventions were associated with a rapid decrease in the number of incident cases. Policies and procedures regarding patients with respiratory viral illnesses in HSCT OPC populations should be formulated and universally reinforced with HSCT clinic staff to prevent the spread of these infections.

KW - Infection control

KW - Parainfluenza

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=75149122733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149122733&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.09.014

DO - 10.1016/j.bbmt.2009.09.014

M3 - Article

C2 - 19781656

AN - SCOPUS:75149122733

VL - 16

SP - 192

EP - 198

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -